EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Poxel stuck to its third-quarter target for a filing for approval of imeglimin in Japan despite warning investors that the COVID-19 pandemic is likely to affect other aspects of its operation. Statement 

> AM-Pharma raised €23 million ($25 million), mainly from Cowen Healthcare Investments. The cash adds to the €116 million AM-Pharma reeled in last year, equipping the Dutch biotech to finalize all its marketing authorization preparation activities. Release  

> Nordic Nanovector outlined plans to close offices and cut its headcount by 20% to extend its cash runway out to 2021. The actions come as the pandemic adds to the enrollment challenges faced by the biotech. Statement 

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

> A clinical trial of patients with community-acquired pneumonia added an arm to evaluate Faron Pharmaceuticals’ intravenous interferon beta-1a in COVID-19 patients. Release 

> Neurimmune and Ethris teamed up to develop mRNA-encoded, neutralizing anti-SARS-CoV-2 antibodies. The partners plan to be in the clinic in the fourth quarter. Statement  

> Redx Pharma secured a £5 million short-term loan from Redmile, the group trying to buy the British biotech. Release 

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.